Advaxis to Participate in Canaccord Genuity Orphan Drug One-on-One Day

[GlobeNewswire] – PRINCETON, N.J. — Advaxis, Inc. , a biotechnology company developing the next generation of cancer immunotherapies, announced that it will participate in the Canaccord Genuity Orphan Drug One-on-One Day, … more

View todays social media effects on ADXS

View the latest stocks trending across Twitter. Click to view dashboard

See who Advaxis is hiring next, click here to view